Top Markets
Coin of the day
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
株式のランク #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
株価
$0.55
最終同期: 2025-02-11
時価総額
$28.90M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Marinus Pharmaceuticals, Inc. (MRNS)

カテゴリー

Marinus Pharmaceuticals, Inc.(MRNS)のP/E比率
August 2026 時点のP/E比率 TTM -0.21
Marinus Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は -0.21 です。2022 年末時点での P/E は -1.96 でした。
Marinus Pharmaceuticals, Inc. の P/E 比率の履歴(2012 〜 2026)
各年末のP/E比率
P/E比率 変化
2026 (TTM) -0.21 -79.70%
2023 -1.03 -47.31%
2022 -1.96 83.00%
2021 -1.07 -14.10%
2020 -1.25 127.96%
2019 -0.55 -31.48%
2018 -0.80 -68.56%
2017 -2.54 1,378.30%
2016 -0.17 -85.01%
2015 -1.15 -23.59%
2014 -1.50 -50.96%
2013 -3.06 -73.27%
2012 -11.45 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差
29.20 -14,064.75%
US
-7.93 3,694.74%
US
30.62 -14,743.33%
NL
32.46 -15,624.10%
AU
- -
CH
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。